Ismail Sari

Ismail Sari

Auto-generated profile, based on publicly available information

Ismail Sari

Mem Atasehir Hosp, Clin Hematol, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2023 in Hamidiye Medical Journal
Verified
Journal Article
Closed access
TÖTuba Erürker Öztürk
Tuba Erürker Öztürk
AKAli Keskin
Ali Keskin
CÖCan Özlü
Can Özlü
İSİsmail Sarı
İsmail Sarı
SHSibel Hacioglu
Sibel Hacioglu
IGİlKay Güler
İlKay Güler

24 August 2022 in Turkish Journal of Hematology
Verified
Journal Article
Open access
OKOmur Kayikci
Omur Kayikci
OMOzgur Mehtap
Ozgur Mehtap
ISIsmail Sari
Ismail Sari
FDFatih Demirkan
Fatih Demirkan
CBCengiz Beyan
Cengiz Beyan
ETEmre Tekgunduz
Emre Tekgunduz
Objective: Peripheral T-cell lymphomas (PTCLs) are an uncommon and quite heterogeneous group of disorders, representing only 10%-15% of all non-Hodgkin lymphomas. Although both molecular and clinical studies have increased in recent years, we still have little knowledge regarding real-life practice with PTCLs. In this study, we aimed to investigate the clinical characteristics and treatment outcomes of a large population-based cohort of patients presenting with systemic non-cutaneous PTCL. Materials and Methods: We conducted a multicenter retrospective analysis of 190 patients consecutively diagnosed and treated with non-cutaneous PTCLs between 2008 and 2016. Results: Considering all first-line treatment combinations, the overall response rate was 65.9% with 49.4% complete remission (n=81) and 16.5% partial response (n=27). The 5-year overall survival and event-free survival rates were significantly different between the transplant and non-transplant groups (p<0.01, and p=0.033, respectively). Conclusion: The retrospective analysis of a large volume of real-life data on the Turkish experience regarding non-cutaneous PTCL patients showed consistent results compared to other unselected PTCL cohorts with some minor differences in terms of survival and transplantation outcomes. The long-term outcome of patients who receive autologous hematopoietic cell transplantation as part of upfront consolidation or salvage therapy is favorable compared to patients who are unable to receive high-dose therapy.